Compare General Motors Company (GM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs GeneDx Holdings Corp — how do they compare? General Motors Company trades at $82.43 (market cap $72.17B), while GeneDx Holdings Corp trades at $68.16 (market cap $2.02B). The key difference: General Motors Company is far larger — about 35.7× GeneDx Holdings Corp's market cap, and General Motors Company pays a 0.88% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and GeneDx Holdings Corp for 19 Days on average.
| GM | WGS | |
|---|---|---|
Market Cap | $72.17B | $2.02B |
Volume | 4,900,304 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $167.51 |
52-Week Low | $55.35 | $34.51 |
Typical Hold Time | 83 Days | 19 Days |
Enterprise Value | $175.15B | $2.05B |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $82.34, up 1.67% with recent earnings beats but faces bearish technical signals. The company reported declining Q3 2026 vehicle sales of 5.5% amid EV market challenges, while maintaining strong cash flow from operations at $26.87B in 2025. Valuation metrics show a P/E of 36.72 and P/S of 0.42, with analyst consensus favoring a Buy rating and $102.08 price target.
GM's outlook is mixed with solid fundamentals offset by near-term headwinds. Investment opportunities include potential regulatory savings of $20.4B from eased fuel economy rules and consistent earnings outperformance. Key risks involve competitive pressure from Asian automakers, declining market share, and profitability pressures with net margins at 1.05%.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
